Standardized SEC financial data for MADRIGAL PHARMACEUTICALS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001157601 · NASDAQ · Pharmaceutical Preparations.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $180.1M | $958.4M |
| Cost of revenue | — | — | $0 | $0 | $6.2M | — |
| Gross profit | — | — | $0 | $0 |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.0M | $36.3M | $358.8M | $634.1M | $931.3M | $203.8M |
| Inventory | — | — | — | $0 | $34.1M | $74.8M |
| Total current assets | $285.2M | $271.7M | $361.4M | $637.3M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/MDGL/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/MDGL/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $173.9M |
| — |
| R&D expense | $184.8M | $205.2M | $245.4M | $272.4M | $236.7M | $388.5M |
| SG&A expense | $21.9M | $37.3M | $48.1M | $108.1M | $435.1M | $813.8M |
| Operating income | -$206.7M | -$242.5M | -$293.6M | -$380.5M | -$497.9M | -$300.1M |
| EBITDA | -$206.2M | -$242.1M | -$293.1M | -$380.0M | -$496.8M | -$298.6M |
| Interest expense | $0 | $0 | $4.0M | $12.7M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$202.2M | -$241.8M | -$295.4M | -$373.6M | -$465.9M | -$288.3M |
| EPS (diluted) | $-13.09 | $-14.63 | $-17.23 | $-19.99 | $-21.90 | $-12.85 |
Standardized from MADRIGAL PHARMACEUTICALS, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $1.03B |
| $1.25B |
| Property, plant & equipment | $1.0M | $851K | $601K | $1.6M | $2.2M | $1.5M |
| Total assets | $287.0M | $273.3M | $362.6M | $640.5M | $1.04B | $1.26B |
| Total current liabilities | $46.6M | $76.8M | $115.9M | $118.5M | $169.3M | $310.3M |
| Long-term debt | — | $0 | $69.7M | $115.5M | $117.6M | $339.9M |
| Total debt | — | $0 | $69.7M | $115.5M | $117.6M | $339.9M |
| Total liabilities | $47.0M | $77.2M | $165.2M | $235.2M | $287.9M | $656.9M |
| Retained earnings | -$425.5M | -$667.3M | -$962.7M | -$1.34B | -$1.80B | -$2.09B |
| Total equity | $240.0M | $196.1M | $197.4M | $405.3M | $754.4M | $602.7M |